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El trastorno del espectro autista (TEA) es una afección del desarrollo neurológico que tiene un 
mecanismo etiológico biológico poco claro. La literatura sugiere una relación estrecha entre la 
microbiota intestinal y el desarrollo del sistema nervioso central, neuroinmune y 
neuroendocrino. Las nuevas teorías y estrategias para el manejo del TEA se han enfocado en 
el eje cerebro-intestinos a través de la terapia de transferencia de microbiota. Se realizó una 
revisión sistemática de la literatura sobre la eficacia y la seguridad de la terapia de transferencia 
de microbiota para el tratamiento de los síntomas en niños con TEA. La búsqueda se realizó el 
19 de abril de 2018 en cinco bases de datos. Se identificó un documento que incluía 18 
pacientes tratados, que presentaron mejoras clínicas significativas en los síntomas 
gastrointestinales y relacionados con el TEA. La causalidad y la correlación de la intervención 
y los resultados esperados no pueden asumirse con la evidencia actual. Además, no se pueden 
hacer recomendaciones sobre la efectividad o seguridad de la terapia de transferencia de 
microbiota en niños con TEA. Se requieren ensayos clínicos aleatorios, controlados con 
placebo, doble ciego y protocolos clínicos para esta intervención. 
Palabras clave: terapia de transferencia de microbiota, trastorno del espectro autista (TEA), 




Autism spectrum disorder (ASD) is a neurodevelopmental condition that has an unclear 
biological etiologic mechanism. Literature suggest a close relation between the gut microbiota 
and the central nervous system development, neuroimmune and neuroendocrine systems. New 
theories and strategies target the management of ASD, by focusing on the brain-gut axis 
through microbiota transfer therapy. We conducted a systematic literature review on the 
efficacy and safety of the microbiota transfer therapy for the management of symptoms in 
children with ASD. The search was conducted on the 19th of April 2018 in five databases. One 
paper was identified that included 18 patients treated, with significant clinical improvements 
in the gastrointestinal and ASD related symptoms. The causality and correlation of the 
intervention and the expected outcomes cannot be assumed with the current evidence. 
Moreover, recommendations about effectiveness or safety of microbiota transfer therapy in 
children with ASD cannot be made. Randomized, placebo-controlled, double-blind control 
trials and clinical protocols for the intervention are needed. 
 
Key words: microbiota transfer therapy, autism spectrum disorder (ASD), microbiome, 





Este trabajo de titulación tiene la intención de ser un producto publicable, por lo que su 
estructura y extensión siguen las  recomendaciones de guías internacionales de revisiones 
sistematicas de la literatura. 
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Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by 
impaired communication, impaired reciprocal social interaction, and restricted, repetitive 
patterns of behavior or interests (Faras, Al Ateeqi, & Tidmarsh, 2010). The symptoms of 
ASD are typically observed in the early childhood, and as ASD is a spectrum, the 
manifestations vary greatly depending on the chronological age, the developmental level, and 
the severity of the patient’s condition (American Psychiatric Association, 2013). Today, the 
ASD term replaces the previous term “pervasive developmental disorder”, and does not use 
the subtypes of Asperger’s disorder, Rett’s disorder and childhood disintegrative disorder 
(Ousley & Cermak, 2014). Currently, ASD includes specifiers to indicate the type of 
impairment and the severity level and encompasses disorders previously referred as 
childhood autism, Kanner’s autism, high-functioning autism, early infantile autism, among 
others 2(American Psychiatric Association, 2013). In the past couple of decades, the 
prevalence of ASD has increased, reaching 1%~2%, partially because of changes in the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-V) diagnostic criteria and 
patients being diagnosed at a younger age (Park et al., 2016). Standardized research 
assessment tools have been designed following the DSM-IV criteria. Such tools include the 
Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation 
Schedule (ADOS) (Lyall et al., 2017). 
 
Etiologic theories of ASD have changed over the years. It is currently accepted that 
ASD is not a single disorder, though a multi-factorial disorder that has genetic and non-
genetic risk factors involved. Causes related to genetics are estimated to be present in 10% to 
20% of patients with ASD (Park et al., 2016).  Researchers suggested that ASD is the result 
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of a complex interaction between genetic and environmental risk factors. The specific neural 
mechanism remains unclear, although literature suggest a close relation between the gut 
microbiota and the central nervous system development, neuroimmune and neuroendocrine 
systems (Cani & Knauf, 2016)(Martin & Mayer, 2017). This evidence has led to the 
development of new theories and strategies for the management of ASD, by focusing on the 
brain-gut axis through microbiota transfer therapy (Choi & Cho, 2016)(Yang, Tian, & Yang, 
2018). Children with ASD have been targeted as a relevant interventional group for using 
microbiota transfer therapy. They tend to present an impaired gut microbiota (dysbiosis), 
gastrointestinal symptoms that are related to the severity of the ASD, an increased use of 
antibiotics and often different diets in comparison with neurotypical individuals (Yang et al., 
2018)(Cryan & Dinan, 2012).   
 
The gut-brain axis has been described to be a bidirectional communication of the gut 
microbiota and the central nervous system (Falsaperla et al., 2017). The gut of humans is 
populated by 1x1013 to 1x1014 microorganisms belonging to more than 1000 species (Yang et 
al., 2018). Their molecular communication includes an endocrine pathway with cortisol, an 
immunologic pathway with several cytokines and a neural pathway with the vagus and 
enteric nervous system (Kennedy et al., 2016)(Yang et al., 2018). These bidirectional 
pathways control the permeability and barrier function of the gut, therefore, the composition 
of the microbiota. Although, the probiotic agents, defined as a living being that positively 
influence health when ingested, and the gut microbiota can alter the concentration of 
cytokines and short-fatty acids (SCFA) which have a direct action in the brain function 
(Cryan & Dinan, 2012). Other studies support the genomeceutical theory, which propose that 
some compounds are able to affect gene expression in cells and the gene products, such as 
proteins and RNA (Brudnak, 2001). Ultimately, the genomeceutical compounds increase the 
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expression of dipeptidyl peptidase-IV, a molecule that has shown to be downregulated in 
ASD and it is even used for ASD diagnosis. Furthermore, the gut-associated lymphoid tissue 
(GALT) has been described as one of the elements involved in the pathophysiology of autism, 
through molecular mechanisms not completely identified yet (Felice & O’Mahony, 
2017)(Brudnak, 2001). 
 
In the past years, microbiota transfer therapy has gathered interest from researches 
and efforts to develop a novel intervention for the management and clinical improvement of 
different pathologies, including ASD (Colman & Rubin, 2014). Microbiota transfer therapy 
aims to restore the gut microbiota of the receiver through the infusion of donor feces to the 
gastrointestinal tract via oral capsules, endoscopic stomach, duodenum, jejunum, ileum, 
coecum or sigmoid infusions or rectal enema infusions (Rossen, 2015)(Choi & Cho, 2016). 
Recent evidence suggests that the microbiota transfer therapy affects the pathophysiology of 
several brain disorders, such as ASD, Parkinson disease, chronic pain, and disorders in mood 
and affect (Martin & Mayer, 2017)(Yang et al., 2018). Microbiota transfer therapy has shown 
to be a durable engraftment of the donor microorganisms and increases the number of species 
present in the receiver’s gut microbiota (Kelly et al., 2015). There is already evidence 
showing its efficacy for different gastrointestinal diseases, such as inflammatory bowel 
disease, metabolic syndrome, irritable bowel syndrome, and Clostridium difficile infection 
(Rossen, 2015). As a novel therapy, there is still no protocol for using microbiota transfer 
therapy for the management of the different pathologies. However in 2010, a workgroup with 
several societies proposed a protocol for the treatment of Clostridium difficile infection with 
microbiota transfer therapy, including the indications, donor selection criteria, recipient 
exclusion criteria, means of administering stool, and the evaluation of the success (Bakken et 
al., 2011). There are still questions about the safety of the microbiota transfer therapy, as it 
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has the possibility of transmitting infectious agents (Choi & Cho, 2016). Therefore, arduous 
screening tests should be performed before the procedure is done, and a strict selection 
criterion for the donor. There are potential adverse events in microbiota transfer therapy, that 
can be divided in minor events and serious events (Hefazi et al., 2017)(Choi & Cho, 2016).   
 
Until now, no systematic literature review of clinical trials, assessing the use of 
microbiota transfer therapy in children with ASD has been conducted. The aim of this study 
is to perform a systematic literature review on the efficacy and safety of the microbiota 




This study was made following the 27 items of the PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses) statement to report a systematic review. 
No preview review protocol was found for Microbiota Transfer Therapy for the Management 
of Autism Spectrum Disorder in children.  This systematic literature review and the protocol 
was not registered before the start of the study. This type of study has excepted from the 
review of an ethics committee.  
SEARCH STRATEGY  
Searches peer-reviewed were performed in five different databases, MEDLINE via 
PubMed, LILACS IBECS via BVS, EMBASE via Ovid, Scopus and Cochrane Library.  The 
search was conducted on the 19th of April 2018 for all the databases. A list of search terms 
was used for each database (Appendix 1). A cross-reference was conducted in the paper 
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identified in this systematic literature review.  Finally, a hand search of reference listings was 
conducted.  
STUDY ELIGIBILITY 
To be included, the papers had to meet the following selection criteria. Study design, 
with randomized controlled trials, quasi-randomized control trials or control trials. 
Population, with children with autism spectrum disorder (age limitation according to each 
study). Intervention, with microbiota transfer therapy. Study Outcome, with efficacy or safety 
outcomes. And no language limitation. 
DATA EXTRACTION AND ANALYSIS 
The application EndNote® was used to extract the information of the manuscripts. An 
automatic deduplication was made. Two reviewers (P.D.E and L.E.G) independently assessed 
the titles and abstracts of the database using the selection criteria. Discrepancies about the 
assessment were solved with discussion until a consensus was reached between P.D.E. and 
L.E.G. If the information of the database was not enough to use the selection criteria, the full 
manuscript was retrieved.  
QUALITY ASSESSMENT 
To assess the risk of bias in estimates of the comparative effectiveness of the study in 
the included in this systematic literature review, the Risk Of Bias In Non-randomized Studies 
– of Interventions (ROBINS-I) was used (NCBI, n.d.)(Sterne et al., 2016).  
RESULTS 
Five thousand two hundred ninety-seven papers were identified after automatic 
deduplication (PRISMA flowchart, Figure 1). From those papers, 104 were identified as 
duplicates, 4,422 were not the study type of interest, 106 papers were not about humans, 621 
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were not about children with ASD, and 30 were not about microbiota transfer therapy. This 
exclusion criteria left 14 papers to be included for the full text review. From those 14 papers, 
12 of them were not the study type of interest and one was not about children with autistic 
spectrum disorder. One study was included in the final review. No additional studies were 
identified along with the hand searches. 
 
The study identified is an open-label trial to investigate the safety, tolerability and 
efficacy of microbiota transfer therapy for gastrointestinal and behavior symptoms in children 
with ASD. The study was published in 2017 (Kang et al., 2017). A total of 18 children 
participated, between ages of seven to 16 years old that presented moderate to severe 
gastrointestinal problems. Twenty neurotypical children were used as control group. The 
protocol used for the microbiota transfer therapy was a 14 days of oral vancomycin initial 
treatment, then a 12 to 24 hours of fasting, followed by a high initial dose of standardized 
human microbiota in oral or rectal infusions. Subsequently, a maintenance oral dose with a 
gastric protector was given for seven to eight weeks. Eight weeks later a follow up was made 
after the end of the treatment. In total, 18 weeks was the time required for the study including 
the treatment and the follow up.  
 
In the study retrieved, assessment of the gastrointestinal symptoms was made through 
the Gastrointestinal Symptom Rating Scale and the daily stool records. While the assessment 
for the autism and related symptoms was made through the ADI-R interview, the Parent 
Global Impression III (PGI-III), among other scales. After the microbiota transfer therapy 
intervention, children with ASD showed that their bacteria diversity in the gut was 
significantly increased compared with their baseline and continued like that for the eight 
weeks of follow up. These assessments showed substantial changes in gastrointestinal 
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symptoms, such as constipation, diarrhea, abdominal pain and indigestion. ASD symptoms 
showed significant improvements during the treatment and no reversion of the effects during 
the follow up. The score on CARS (Childhood Autism Rating Scale) that rates ASD 
symptoms, showed a decreased of 22% when the treatment was over, and 24% after eight 
weeks of no treatment. Using other scales, like the SRS (The Social Responsiveness Scale) 
and the ABC (The Autism Behavior Checklist), the improvements in the participants scores 
was found. The average developmental age was found to be increased in 1.4 yeas with a 
p<0.001 with the VABS-II (Vineland Adaptive Behavior Scale II) score. No significant 
difference was found in the clinical outcomes related if the first dose of the microbiota 
transfer therapy was given rectally or orally. Other findings include that microbiota transfer 
therapy was a safe and well tolerated intervention, with some transitory adverse effects, 
including hyperactivity and aggression during the first phase of vancomycin treatment.  
 
The risk of bias of the study identified was made by the ROBINS-I (Risk Of Bias In 
Non-randomized Studies - of Intervention) assessment tool (Sterne et al., 2016). The risk of 
bias judgement can be considered low, moderate, serious, critical or no information. The risk 
of bias due to confounding was considered serious. Although the risk of bias in selection of 
participants into the study, in classification of interventions, due to deviations from intended 
interventions, and due to missing data was considered low. Moreover, the bias in 
measurement of outcomes was considered moderate. An overall bias of the study was 






To date, this is the only systematic literature review on microbiota transfer therapy on 
children with ASD. After the screening, one study was identified. The study had 18 children 
for the intervention and 20 neurotypical children as a control group. Significant clinical 
improvements were found in the children after the microbiota transfer therapy, in the 
gastrointestinal and ASD related symptoms (Kang et al., 2017). These results were 
maintained on the eight follow up weeks after the end of the treatment. An update of this 
study was recently published in April 2019, following up the results of this first study (Kang 
et al., 2019). All 18 participants with ASD were re-evaluated, showing a significant 
improvement in both gastrointestinal and ASD behavior symptoms since the end of the 
treatment. Two years after the intervention, the changes in the microbiota persisted with 
relative abundances of Bifidobacteria and Prevotella (Kang et al., 2019). In a published 
observation, two children showed improvement in their ASD symptoms after fecal 
microbiota therapy and five children after several weeks of receiving cultured Bacteroidetes 
and Clostridia every day (Aroniadis & Brandt, 2013).  
 
The brain-gut axis involves complex communication and metabolic mechanisms that 
are still not fully understood. Several pathophysiologic pathways have been proposed, 
hypothesizing the relation between the microbiota composition with different neurological 
conditions, nevertheless still needs further evidence to clarify the function of this axis. Taking 
in consideration that children with ASD present a pattern of dysbiosis, the microbiota transfer 
therapy has raised attention as a novel intervention for the management of ASD patients. 
However, it is still not clear if there is a direct relation between ASD and the alteration in 
their gut microbiota and therefore, if the change in the microbiota directly influences the 
different gastrointestinal and clinical symptoms of ASD.   Besides, microbiota transfer 
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therapy is a growing field in medicine for management of several diseases. It is not a new 
therapeutically modality however it has received public attention from the media in the past 
years. The first report of fecal material given to patients with gastroenterological illness was 
in China by Ge Hong (Aroniadis & Brandt, 2013). The use of fecal enemas was reported in 
1958 as an adjunct treatment of pseudomembranous enterocolitis (Eiseman, Silen, Bascom, 
& Kauvar, 1958). Today, microbiota transfer therapy is extensively used for Clostridium 
difficile infection, inflammatory bowel disease, and irritable bowel syndrome management 
(Sha et al., 2014). The evidence is growing around fecal microbiota therapy and its 
applications in other fields of medicine, including ASD patients. Efficacy and safety data 
have been recorded mainly in adults, while in children it has not been studied so widely.  
 
The study identified in the systematic review was assessed by the ROBINS-I risk of 
bias assessment tool. The biggest risk of bias was due to confounding, as the study was open 
label and did not explain an appropriate analysis method for controlling all the important 
confounding domains. The other items assessed for bias were scored low or moderate, giving 
a low overall risk of bias.  
LIMITATIONS 
Reporting the efficacy and safety of microbiota transfer therapy in children with ASD 
is limited by the absence of randomized clinical trials in the field. Only one open label study 
reported to date (Kang et al., 2017). Even though the intervention has been described as 
effective and safe in the study found, the 18 children of this study are not enough to make 
recommendations for future application of the microbiota transfer therapy intervention in 
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ASD children. The causality and correlation of the intervention and the expected outcomes 
cannot be assumed with the current evidence. 
CONCLUSIONS 
This systematic literature review shows that the evidence is not strong enough to 
make recommendations about effectiveness or safety of microbiota transfer therapy in 
children with ASD. Randomized, placebo-controlled, double-blind control trials and clinical 
protocols for the intervention are needed. Although, at the moment, three clinical trials have 
been identified related to microbiota transfer therapy with ASD patients. One that will target 
ASD and gastrointestinal disorders  in children (“Efficacy, Safety, and Tolerability Study of 
Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and 
Associated GI Symptoms (SPROUT) - Full Text View - ClinicalTrials.gov,” n.d.), another 
one with adults (“Microbiota Transfer Therapy for Adults With Autism Spectrum Disorder 
(ASD) Who Have Gastrointestinal Disorders - Full Text View - ClinicalTrials.gov,” n.d.) and 
the other one in children and young adults (“The Gut-Brain Study - Full Text View - 
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Figure 1  




ANNEX A: SEARCH TERMS FOR EACH DATABASE  
Search terms_MEDLINE via PUBMED 
Items # Search terms 
Population_children 
#1 Child[MeSH] OR Infant[MeSH] OR pediatrics[MeSH] 
#2 
infant[TIAB] OR infant*[TIAB] OR newborn[TIAB] 
OR newborn*[TIAB] OR neonat*[TIAB] OR 
baby[TIAB] OR babies[TIAB] OR child[TIAB] OR 
child*[TIAB] OR schoolchil*[TIAB] OR 
preschoo*[TIAB] OR toddler[TIAB] OR 
toddler*[TIAB] OR girl[TIAB] OR girl*[TIAB] OR 
boy[TIAB] or boy*[TIAB] OR pediatri*[TIAB] OR 
paediatri*[TIAB]  
#3 #1 OR #2 
Population_austism 
#4 
"Child Development Disorders, Pervasive"[MeSH] OR 
"Intellectual Disability"[MeSH] OR "Mental 
Disorders"[MeSH] 
#5 
autis*[TIAB] OR "pervasiv*"[TIAB] OR PDD[TIAB] 
OR "language"[TIAB] OR speech[TIAB] OR 
schizophren*[TIAB] OR kanner[TIAB] OR 
kanner*[TIAB] OR asperge*[TIAB] OR 
cogniti*[TIAB] OR behavio*[TIAB] OR 
neurobehavio*[TIAB] 
#6 #4 OR #5 
Population_total #7 #3 AND #6 
Intervention_faecal 
#8 Microbiota[MeSH] OR Feces[MeSH] 
#9 
faecal[TIAB] OR fecal[TIAB] OR stool[TIAB] OR 
gut[TIAB] OR microbio*[TIAB] OR feces[TIAB] OR 
microflor*[TIAB] OR bacteri*[TIAB] 
#10 #8 OR #9 
intervention_transplant 
#11 transplants[MeSH] OR transplantation[MeSH] 
#12 
infusio*[TIAB] OR transplan*[TIAB] OR 
transfer[TIAB] OR therap*[TIAB]  OR graft*[TIAB] 
OR graft[TIAB] 
#13 #11 OR #12 
intervention_faecal 
transplant  
#14 "Fecal Microbiota Transplantation"[MeSH] 
intevrention_total #15 (#10 AND #13) OR #14 








Search_LILACS_IBECS via BVS 
Items # Search terms 
Population_children 
#1 
mh:("^dniño" OR "^dniño preescolar" OR "^drecién 
nacido" OR Child OR Infant OR pediatrics) 
#2 
tw:(nin$ OR "recien nacido" OR "recien nacidos" OR 
bebe OR bebes OR chico OR chicos OR chica OR 
chicas OR infant OR infant$ OR newborn OR 
newborn$ OR neonat$ OR baby OR babies OR child$ 
OR child OR schoolchil$ OR preschool$ OR toddler 
OR toddler$ OR girl OR girl$ OR boy OR boy$ OR 
pediatric OR pediatric$ OR paediatric OR paediatric$) 
#3 #1 OR #2 
Population_austism 
#4 
mh:("^dtrastornos del lenguaje" OR "^dTrastorno 
Autístico^sgenet" OR "^dtrastorno autístico^sterap" 
OR "^dtrastorno autístico^spsicol" OR "^dtrastorno 
autístico^sdiag" OR "^dtrastorno del espectro del 
autismo^sterap" OR "^dtrastorno del espectro del 
autismo^spsicol" OR "^dtrastorno del espectro del 
autismo^sdiag" OR "^dTrastorno Autístico^sgenet" OR 
"Child Development Disorders, Pervasive" OR 
"Intellectual Disability" OR "Mental Disorders") 
#5 
tw:(desenvolv$ OR idom$ OR OR habla OR lenguaje 
OR esquizofre$ OR comportamient$ OR autis$ OR 
pervasiv$ OR PDD OR language OR speech OR 
schizophren$ OR kanner$ OR kanner OR asperge$ OR 
cogniti$ OR behavio$ OR neurobehavio$) 
#6 #4 OR #5 
Population_total #7 #3 AND #6 
Intervention_faecal 
#8 
mh: ("^dmicrobiota^sfisiol" OR "^dHeces" OR 
"^dmicrobiota^sinmunol" OR "Heces/microbiología" 
OR Microbiota OR Feces OR "Heces/microbiología") 
#9 
tw:(faecal OR fecal OR stool OR intesti$ OR gut OR 
microbio$ OR feces OR heces OR microflor$ OR 
bacteri$) 
#10 #8 OR #9 
intervention_transplant 
#11 
mh:(transplants OR transplantation OR "Trasplante" 
OR "^dtrasplante de órganos^smétodos" OR 
"^dtrasplante") 
#12 
tw:(trasplan$ OR infusio$ OR transpla$ OR transfer 
OR transfer$ OR therap$ OR terapi$  OR graft OR 
graft$ OR injerto OR injerto$) 
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mh:("Fecal Microbiota Transplantation" OR 
"Trasplante de Microbiota Fecal" OR "Diarrea/terapia") 
intevrention_total #15 (#10 AND #13) OR #14 
Total #16 #7 AND #15 
   
Search terms_EMBASE via Ovid 
Items # Search terms 
Population_children 
#1 Child/ OR Infant/ OR pediatrics/ 
#2 
(infant OR infant* OR newborn OR newborn* OR 
neonat* OR baby OR babies OR child OR child* OR 
schoolchil* OR preschoo* OR toddler OR toddler* OR 
girl OR girl* OR boy or boy* OR pediatri* OR 
paediatri*).ab,ti 
#3 1 OR 2 
Population_austism 
#4 
"Intellectual impairment"/ OR "Mental disease"/ OR 
autism/ OR "infantile autism"/ OR "pervasive 
developmental disorder not otherwise specified"/ 
#5 
(autis* OR "pervasive developmental disorder*" OR 
PDD OR "language" OR speech OR schizophren* OR 
kanner* OR asperger* OR cogniti* OR behavio* OR 
neurobehavio*).ab,ti 
#6 4 OR 5 
Population_total #7 3 AND 6 
Intervention_faecal 
#8 Microflora/ OR Feces/ OR "feces microflora"/ 
#9 
(faecal OR fecal OR stool OR gut OR microbio* OR 
feces OR microflor* OR bacteri*).ab,ti 
#10 8 OR 9 
Intervention_transplant 
#11 transplantation/ OR infusion/ 
#12 
(infusio* OR transplan* OR transfer OR therap*  OR 
graft* OR graft).ab,ti 
#13 11 OR 12 
Intervention_faecal 
transplant  #14 "Fecal Microbiota Transplantation"/ 
Intervention_total #15 (10 AND 13) OR 14 












Search terms_SCOPUS via SCOPUS 
Items # Search terms 
Population_children 
#1 
TITLE-ABS-KEY (infant OR infant* OR newborn OR 
newborn* OR neonat* OR baby OR babies OR child 
OR child* OR schoolchil* OR preschoo* OR toddler 
OR toddler* OR girl OR girl* OR boy or boy* OR 
pediatri* OR paediatri*) 
Population_austism 
#2 
TITLE-ABS-KEY (autis* OR "pervasiv*" OR PDD 
OR "language" OR speech OR schizophren* OR 
kanner OR kanner* OR asperge* OR cogniti* OR 
behavio* OR neurobehavio*) 
Intervention_faecal 
#3 
TITLE-ABS-KEY (faecal OR fecal OR stool OR gut 
OR microbio* OR feces OR microflor* OR bacteri*) 
Intervention_transplant 
#4 
TITLE-ABS-KEY (infusio* OR transplan* OR transfer 
OR therap*  OR graft* OR graft) 
Total #5 #1 AND #2 AND #3 AND #4 
   
Search_COCHRANE via COCHRANE 
Items # Search terms 
Population_children 
#1 MeSH descriptor: [Child] explode all trees 
#2 MeSH descriptor: [Infant] explode all trees 
#3 MeSH descriptor: [pediatrics] explode all trees 
#4 
(infant OR infant* OR newborn OR newborn* OR 
neonat* OR baby OR babies OR child OR child* OR 
schoolchil* OR preschoo* OR toddler OR toddler* OR 
girl OR girl* OR boy or boy* OR pediatri* OR 
paediatri*):ab,ti 
#5 #1 OR #2 OR #3 OR #4 
Population_austism 
#6 
MeSH descriptor: ["Child Development Disorders, 
Pervasive"] explode all trees 
#7 
MeSH descriptor: ["Intellectual Disability"] explode all 
trees 
#8 
MeSH descriptor: ["Mental Disorders"] explode all 
trees 
#9 
(autis* OR "pervasiv*" OR PDD OR "language" OR 
speech OR schizophren* OR kanner OR kanner* OR 
asperge* OR cogniti* OR behavio* OR 
neurobehavio*):ab,ti 
#10 #6 OR #7 OR #8 OR #9 
Population_total #11 #5 AND #10 
Intervention_faecal #12 MeSH descriptor: [Microbiota] explode all trees 
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#13 MeSH descriptor: [Feces] explode all trees 
#14 
(faecal OR fecal OR stool OR gut OR microbio* OR 
feces OR microflor* OR bacteri*):ab,ti 
#15 #12 OR #13 OR #14 
Intervention_transplant 
#16 MeSH descriptor: [transplants] explode all trees 
#17 MeSH descriptor: [transplantation] explode all trees 
#18 
(infusio* OR transplan* OR transfer OR therap*  OR 
graft* OR graft):ab,ti 
#19 #16 OR #17 OR #18 
Intervention_faecal 
transplant  #20 
MeSH descriptor: ["Fecal Microbiota Transplantation"] 
explode all trees 
Intervention_total #21 (#15 AND #19) OR #20 
Total #22 #11 AND #21 
 
